BRAF and colorectal carcinoma: Since capecitabine and oxaliplatin were administrated in BRAF mutant CRC patients routinely in the clinic, we checked whether these inhibitors alone could provide increased sensitivity to dabrafenib insensitivity in HT-29 cells.